{"organizations": [], "uuid": "a19b6d5f89551b208673e42f1ba3eb89213f093c", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180509.html", "section_title": "Archive News &amp; Video for Wednesday, 09 May 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-vtv-therapeutics-announces-company/brief-vtv-therapeutics-announces-company-will-pre-specify-new-subgroup-with-the-fda-idUSASC0A16A", "country": "US", "domain_rank": 408, "title": "BRIEF-VTV Therapeutics Announces Company Will Pre-Specify New Subgroup With The FDA", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.849, "site_type": "news", "published": "2018-05-10T04:37:00.000+03:00", "replies_count": 0, "uuid": "a19b6d5f89551b208673e42f1ba3eb89213f093c"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-vtv-therapeutics-announces-company/brief-vtv-therapeutics-announces-company-will-pre-specify-new-subgroup-with-the-fda-idUSASC0A16A", "ord_in_thread": 0, "title": "BRIEF-VTV Therapeutics Announces Company Will Pre-Specify New Subgroup With The FDA", "locations": [], "entities": {"persons": [{"name": "alzheimer", "sentiment": "none"}], "locations": [], "organizations": [{"name": "fda", "sentiment": "negative"}, {"name": "reuters", "sentiment": "negative"}, {"name": "brief-vtv therapeutics announces company will pre-specify", "sentiment": "negative"}, {"name": "therapeutics inc", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "May 9 (Reuters) - vTv Therapeutics Inc:\n* VTV THERAPEUTICS ANNOUNCES COMPANY WILL PRE-SPECIFY NEW SUBGROUP WITH THE FDA AND REPORT PHASE 3 PART B RESULTS IN JUNE\n* VTV THERAPEUTICS INC - SUBGROUP OF MILD ALZHEIMERâ€™S PATIENTS IN PART A OF PHASE 3 STEADFAST STUDY DEMONSTRATED POSITIVE BENEFIT Source text for Eikon: Further company coverage:\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-05-10T04:37:00.000+03:00", "crawled": "2018-05-10T17:52:37.017+03:00", "highlightTitle": ""}